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Abstract: Diets high in sugar or fat are associated with multiple health conditions,
including binge eating disorder (BED). BED affects approximately 2% of the US adult
population, and occurs more frequently in females. It is important to develop animal
models of palatable food consumption, food seeking, and voluntary physical activity that
may have relevance for BED and other conditions associated with excessive food
intake. The catecholamine uptake blocker and d-amphetamine prodrug
lisdexamfetamine (LDX) is used to treat BED. The present experiments studied the
effect of LDX on food intake and two effort-based choice tasks in female Wistar rats. In
experiment one, three groups of rats received different food exposure conditions in the
home cage randomly spread over several weeks: the chocolate exposure group (CE;
brief access of chocolate and additional lab chow, n=15), a lab chow exposure (LChE)
group was given additional access to lab chow (n=8), and a third group was given
empty food dishes (n=7). In tests of food intake under non-restricted conditions, LDX
(0.1875-1.5 mg/kg IP) significantly reduced intake of both chocolate and chow in the CE
group. In the LChE group, there was a trend towards reduced chow intake induced by
LDX. All rats were trained on a Progressive Ratio/chow feeding choice task, in which
they had a choice between working for high carbohydrate chocolate flavored pellets by
lever pressing vs. approaching and consuming a concurrently available lab chow. The
LChE group and the empty food dish group were combined to create one control group
(n=15). There was a significant overall dose-related suppressive effect of LDX on lever
pressing but no group difference, and no dose x group interaction. LDX significantly
decreased chow intake in the CE group, but not in the control group. In Experiment two,
rats (n=8) were given brief access of chocolate in the home cage randomly spread over
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several weeks. They were then trained on a novel T-Maze task in which they had a
choice to eat freely available chocolate or run on a running wheel. LDX (0.09375-1.5
mg/kg IP) significantly reduced intake of chocolate, and a trend towards reduced
running wheel activity was seen. In conclusion, LDX affected both food intake, foodreinforced operant behavior, and running wheel activity.
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Introduction
Disordered eating, such as what is seen in anorexia nervosa, bulimia nervosa,
and Binge Eating Disorder (BED), is associated with both physical and psychological
disorders. Individuals with eating disorders have increased risks for cardiovascular
problems, neurological dysfunction, decreased immune function and increases in
anxiety (Johnson et al. 2002). This can lead to increased levels of diabetes and
psychiatric disorders later in life (Johnson et al. 2001). Mortality due to eating disorders
is very high in part to factors such as increased rates of smoking, alcoholism and
suicide within the population (Herzog et al. 2000). Implications on reproductive health in
individuals with a history of EDs have also started to come to light, including infertility
and increased risk of miscarriage (O’Brien et al. 2017).
With the release of the DSM-V in 2013, BED was recognized as one of three
specified feeding and eating disorders. Before this time, people with BED were
considered as having an “eating disorder not otherwise specified.” BED’s representation
as a distinct category distinguishes it from overeating, which is a major public health
concern today, but does not encompass all of the psychological symptoms associated
with BED such as the feeling of a lack of control in food consumption. This leads an
individual to consume large amounts of food more rapidly than normal in a short period
of time, typically consuming food until uncomfortably full, even if the person is not
hungry. These episodes occur at least once a week during a 3 month period, and
individuals report being extremely distraught over them (DSM-V; APA 2013). A survey
completed by the World Health Organization (WHO) conducted across 14 different
countries found BED to have a lifetime prevalence rate of 1.4%, with a typical onset
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being in the late teens to early 20’s (Kessler et. al 2013). In the United Sates alone,
BED has a lifetime and 12-month prevalence rate of 0.85% and 0.44% respectively.
(Udo & Grilo 2018). Occurrence is higher in women (3.5%) than in men (2.0%) and has
been shown to be relatively independent of weight but is more common among
overweight and obese individuals (Bruce and Wilfley 1996, Hudson et al. 2007). Diets
high in fat and sugar have been linked to increases in obesity, type 2 diabetes,
hypertension and cardiovascular disease (Guh at el. 2009).
Treatment outcomes for BED are variable based on the treatment used (Wilson
2011). Common treatments for BED include both psychological and pharmacological
interventions. Cognitive behavioral therapy and guided self-help have shown the most
promise in terms of psychological treatments (Ghaderi et al. 2018). Pharmacologically,
many classes of drugs have been looked at, including antidepressants such as the
SSRI fluoxetine (Prozac), anti-obesity, antiepileptic, and anti-addiction medications
(Ghaderi et al. 2018). The d-amphetamine pro-drug lisdexamfetamine (LDX; Vivanse), a
common medication for treating attention deficit hyperactivity disorder, was approved for
the treatment of moderate to severe BED in 2015. As a pro-drug, LDX has a slower on
set and longer lasting effects (Heal et al. 2013). LDX, due to l-lysine being covalently
bound to d-amphetamine, is inactive until it is metabolized within the body, more
specifically within the red blood cells (Pennick 2010, Heal et. al 2013).
Animal models of binge-like feeding behavior have been developed (Hagan et al.
2002, Colantuoni 2003, Avena & Hoebel 2003, Rada et al. 2005, Boggiano & Chandler
2006, Corwin & Wojnicki 2006, Avena et al. 2004, 2006, Heyne et al. 2009; Vickers et
al. 2015; Smith et al. 2015; Smail-Crevier et al. 2018), which involve induction of
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excessive eating of a highly palatable food. After inducing chocolate binging behavior in
rats, Vickers et al. (2015) reported that LDX can reduce chocolate intake in a dosedependent manner during binging sessions. Vickers et al. (2015) highlighted the
effectiveness of LDX at attenuating consumption, but did not look at effort-related
aspects of food seeking or reinforced behavior. The following experiments were
intended to address this.

Experiment One: Operant Conditioning
One characteristic of motivated behavior is that a high degree of effort is often
expended in order to achieve a goal. Behavioral tasks have been developed to look at
effort-related aspects of motivated behavior in both humans and animals (Salamone et
al. 1991, 1994, 2016; Treadway et al. 2009; Randall et al. 2012; Sommer et al. 2014;
Hosking et al. 2015). These tasks include maze procedures that require high physical
activity to obtain reinforcers, operant procedures such as progressive ratio (PROG)
schedules that require increasing levels of work output to obtain reinforcement, and
effort-based decision making tasks (Salamone et al. 2016). Nasser et al. (2008) studied
humans with and without a BED diagnosis using a food-reinforced PROG operant task.
Before the task, subjects were either given water or a drinkable meal. Nasser et al.
(2008) reported that individuals without BED had a significant reduction in the amount of
work they were willing to put into achieving their food reward after receiving the meal
drink, whereas individuals diagnosed with BED did not. These results indicated that
people with BED are not motivated by hunger.
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Because it is critical to employ animal models to study phenomena related to
binge eating on palatable foods, the present experiments studied the effect of LDX on
food intake and food-reinforced effort-based choice in female Wistar rats. Three groups
of rats received different food exposure conditions in the home cage randomly spread
over several weeks: the chocolate exposure group (CE; brief access of chocolate and
additional lab chow, n=15), a lab chow exposure (LChE) group was given additional
access to lab chow (n=8), and a third group was given empty food dishes (n=7).
Chocolate intake in female Wistar rats was studied based upon the Vickers et al. (2015)
procedure. After having experience with their respective exposure conditions, the rats
were tested for the effects of LDX on intake of the different foods (chocolate and
standard lab chow) as well as effort-based choice using the PROG/chow feeding choice
procedure that has been developed in our laboratory (Randall et al. 2012, 2014, 2015;
Yohn et al. 2016 a,b,c). With this task, rats had a choice between working for preferred
high carbohydrate chocolate flavored pellets by lever pressing on the PROG schedule
vs. approaching and consuming a concurrently available but less preferred lab chow.
These procedures allowed for investigation of the effects of LDX on food intake as well
as the tendency to work for food.

Methods
Animals
Singly-housed, adult female, Wistar rats (N = 30 Charles River) weighing
between 226-250 grams on arrival were food restricted to 85% of their free feeding
weights for 16 weeks allowing for modest growth. Water was available ad libitum.
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Starting at 17 weeks, rats were given food ad libitum. All animal procedures were
approved by the Institutional Animal Care and Use Committee.

Operant Training
Using Med Associates operant chambers (28 × 23 × 23 cm), rats were trained to
lever press for high carbohydrate pellets on a FR1 schedule for 3 weeks. Training then
began on the PROG task for 8 weeks (30 min sessions, 5 days a week) after which
freely available lab chow was placed in the box during their session (PROG/chow
choice task) to give them an option of either lever pressing for pellets or approaching
and consuming the lab chow. They remained on the PROG/chow feeding choice task
for the remainder of the experiment. Rats were weighed prior to each operant task. At
week 11 of training on the PROG/chow choice task, the rats were transitioned from
plain high carbohydrate pellets to chocolate flavored high carbohydrate pellets for the
remainder of the experiment. This was done because of previous studies that used
chocolate flavored pellets for operant conditioning studies in rats tested in a binge
eating model (Smith et al. 2015).

Development of chocolate binge-consumption behavior
The rats were randomly assigned to 3 groups: chocolate exposure group (CE;
n=15), lab chow exposure group (LChE; n=8), and empty food dish group (n=7). In the
home cage, a one-day, one-hour exposure to two ceramic dishes took place before the
introduction of chocolate. The exposure schedule mirrored that used by Vickers et al.
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(2015), with rats receiving exposure of 1 of 3 different conditions based on their
assigned group on days 1, 2, 4, 6, 7, 9, 12, 14, 15, 18, 23 and 28. On exposure days, 2
ceramic dishes were placed in the home cage of each rat for 2 hrs. For the first
exposures, the chocolate exposure group was given access to one dish containing
chocolate, and a second, empty dish. Starting on day 7, the chocolate exposure group
had one dish containing chocolate and another containing lab chow. The lab chow
exposure group had a dish containing lab chow and one empty dish, and finally, the
empty food dish group had two empty dishes. After exposure day 28, exposure
continued on a randomized schedule with 2 sessions happening each week. Starting on
day 58, the 2 weekly sessions were split between a morning session and an afternoon
session. Weights of both chocolate and lab chow were taken before and after each
session.

Administration of Lisdexamfetamine (LDX) during food exposure sessions
Doses of LDX were based on experiments completed previously (Yohn et al.
2016b). Starting on week 15 of exposure, IP injections of 0.1875, 0.375, 0.75, 1.5mg/kg
or vehicle (saline) were given to rats once per week in a randomly varied order 60
minutes prior to testing. Drug administration only occurred during afternoon exposure
sessions. Weights of both chocolate and lab chow were taken before and after each
session to determine the effect of LDX on consumption.

Administration of Lisdexamfetamine during operant behavior sessions
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Starting on week 20 of exposure, LDX administration of 0.1875, 0.375, 0.75,
1.5mg/kg or vehicle (saline) was given to rats once per week in a randomly varied order
60 minutes prior to their operant behavior session. Amount of lever pressing and lab
chow consumption were both recorded to determine the effect LDX had on both lever
pressing and chow intake.

Statistical Analyses
A repeated measures of analysis of variance (ANOVA) was used to evaluate the
effect of LDX on the amount of chocolate and chow in grams consumed during a food
intake session. Planned comparisons were used to compare each treatment to the VEH
group. Effect sizes of consumption amounts were determined using partial eta square
values. A factorial ANOVA was used to compare the CE group versus the control group
during the 30-min operant session for both lever pressing (LP) and chow consumption.

Results
Acquisition of Chocolate Binging Behavior, and Body Weight Data
Analysis of the initial acquisition period for chocolate binging behavior was
performed using a repeated measures ANOVA. There was an overall significant effect
of binge session [F(11,154) = 27.379, p < 0.001) Fig. 1]. Chocolate intake increased
dramatically over the first several sessions, leveled off, then decreased slightly when
chow was introduced. Significant linear [F(1,14) = 89.333, p < 0.001)] and quadratic
[F(1,14) = 104.153, p < 0.001)] contrasts were seen, leading to separate analyses of the
sessions before and after chow was introduced. A significant increase across binge
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sessions was seen before chow was introduced (days 1-7 [F(4,56) = 32.421, p < 0.001])
and a small but significant decrease was seen after chow was added to the binge
sessions (days 9-28 [F(6,84) = 3.892, p = 0.002)]). Repeated measures ANOVA
analysis of body weights (Figure 2) over the course of the experiment found a significant
overall effect due to week [F(23, 644) = 195.156, p < 0.001)] but no significant
difference between the CE and control groups [F(1, 28) = 0.119, p = 0.733)], and no
interaction (F(1,23) = 0.738, n.s.). This indicated that despite the occasional exposure to
chocolate, body weight was not affected in the CE group.

Effect of Lisdexamfetamine administration on intake during exposure sessions
Repeated measures ANOVA showed a significant overall effect of LDX on intake
of chocolate [F(4,56) = 7.713, p < 0.001) Fig 3.] and lab chow [F(4,56) = 11.475, p <
0.001 Fig. 3] in the CE group. Planned comparisons analysis found LDX significantly
reduced chocolate consumption at the highest dose of LDX (p < 0.05) and significantly
reduced chow consumption at the two highest doses (p < 0.05) when compared to the
VEH treatment. For the LChE group, the ANOVA approached significance [F(4,28) =
2.533, 0.05 < p < 0.1) Fig 4.], with a strong tendency towards a decrease in chow intake
at the highest dose. Table 1 lists the partial eta squared effect sizes for the actions of
LDX on intake of chocolate and chow across both groups. Moderate to large effect sizes
for all three ANOVAs illustrate a strong trend towards a reduction of consumption in
both groups with very large effect sizes (partial eta squared > 0.40) at the highest dose
of LDX in all three conditions studied.
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Effect of Lisdexamfetamine administration during operant sessions
Factorial ANOVA revealed a significant overall effect of LDX treatment on lever
pressing (PROG/chow choice task) [F(4,112) = 10.739, p < 0.001) Fig. 5], but no
significant group difference, and no significant treatment x group interaction. For chow
consumption, there was a significant overall treatment effect [F(4,112) = 5.905, p <
0.001 Fig. 6]. A group difference was trending towards significance [F(1, 28) = 2.172, p
= 0.072] but a significant treatment x group interaction [F(1, 28) = 4.561, p < 0.05] was
seen. Planned comparisons revealed that LDX significantly reduced lever pressing at
the three highest doses of LDX (p < 0.001) in both groups and significantly reduced
chow consumption at the three highest doses (p < 0.05, 0.001) of the CE group when
compared to the VEH treatment. There was no reduction of chow intake in the
combined control group.

Experiment Two: T-Maze Task
The development of novel animal models in the study of motivation are
necessary in order to continue gaining new insight into this complex aspect of behavior.
Tasks similar to what was highlighted in experiment one use food as an overall
motivating factor. Complications using these types of methods can develop when a
pharmacological agent known to produce appetite suppressing effects is used during
the task. A question arises about whether or not the observed behavioral outcome is
due to factors that are specific to the particular motivational stimulus. Running on a
running wheel (RW) has been shown to be an intrinsically reinforcing activity in rats
(Kagan and Berkun 1954, Collier and Hirsch 1977, Pierce et al. 1986, Iversen 1993),

9

subject to multiple types of reinforcement schedules. A recent study completed in mice
found that when given the option to run on a RW or consume freely available lab chow,
mice consistently chose the RW (Correa et al. 2016). With all of this in mind, in order to
study the effects of LDX using a task that involved a food reinforcer as well as a nonfood reinforcer, a T-Maze task for rats was developed to pit the desire to consume food
against the desire for voluntary physical activity in terms of RW activity.
Using a model similar to what has been developed in mice (Correa et al. 2016), a
RW was placed in one arm of a standard T-Maze, with a palatable food (Cadbury’s Milk
Chocolate) placed in a ceramic bowl in the other. Rats were then placed in the middle of
the maze and given 30 minutes to choose between going back and forth between the
RW and palatable food. LDX was administered once chocolate consumption and RW
activity were stable in terms of baseline levels. This new procedure allowing the animal
to choose between two different motivating factors can be used to tease apart the
changes in behavior that can become muddied with a single motivating factor.

Methods
Animals
Singly-housed, adult female, Wistar rats (N = 8 Charles River) weighing between
226-250 grams on arrival were given water and food ad libitum.

Development of chocolate binge-consumption behavior:

Similar to the procedure used during the operant experiment, a one-day, onehour exposure to a ceramic dish took place in the rat’s home cage before the
10

introduction of chocolate. Rats received exposure of chocolate on days 1, 2, 4, 6, 7, 9,
12, 14, and 15. On exposure days, 1 ceramic dish was placed in the center front of the
home cage of each rat for 1 hour. Weight of chocolate was taken before and after each
session. Amounts given were determined by consumption of the rat in their prior
session. Once binge-like eating behavior was established, chocolate was no longer
given in the home cage but was only offered during the T-Maze task.

T-Maze Apparatus
A Plexiglas T-maze apparatus consisting of a start arm (29X21X21 cm) and two
test arms (99X32X59 cm) was utilized for this task. Within the maze, a clear box
(47.6X25.9X20.9 cm) with a hole (10.3 cm diameter) cut in the front was placed in either
the right or left arm. This box housed the RW (Starr Life Sciences Corp.) apparatus with
an attached counter to record RW rotations during sessions. A wall (32X59 cm) with an
entry hole was placed in front of the box to keep the rats from moving around the box
during early stages of training. The opposite arm contained a ceramic bowl (9 cm
diameter) (PetCo) with ground milk chocolate (Cadbury’s Dairy Milk).

T-Maze Training
RW Training:
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Rats were first introduced to the RW by being placed directly into the box with the
entry hole blocked so they only had access to the RW area for two sessions. On the
third session, the side containing the bowl was blocked off and rats were placed in the
middle of the maze facing the wall. This required the rat to use the entry hole of the RW
box. On the final session the maze was open for the rat to explore both arms with an
empty ceramic bowl placed opposite to the RW. Each session lasted 30 minutes.

Chocolate Training:
After the induction of chocolate binge behavior, rats were blocked in the arm
containing the ceramic bowl and chocolate for two sessions. Sessions 3, 4, and 5, of TMaze chocolate exposure, the rat was placed in the maze with the RW entry hole
blocked off, which allowed access to the open maze but entry only to the chocolate arm.
Each session lasted 30 minutes.

Administration of Lisdexamfetamine (LDX) during T-Maze sessions:
Doses of LDX were based on experiments completed previously (experiment
one). Once consistent RW activity and chocolate consumption was reached in the TMaze, administration of 0.09375, 0.1875, 0.375, 0.75, 1.5mg/kg or vehicle (saline) was
given to rats in a randomly varied order once per week, 60 minutes prior to T-Maze
entry. Weights of chocolate were taken before and after each session, and RW rotations
(complete rotations) were recorded, to determine the effect LDX had on both chocolate
intake and RW activity. Video recordings of sessions were used to determine time spent
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actively or passively interacting with the RW, time spent eating, time spent doing neither
of those activities, and number of side changes and rears.

Statistical Analyses
A repeated measures analysis of variance (ANOVA) was used to evaluate the
acquisition of chocolate binging behavior and the effects of LDX on the percent baseline
amount of chocolate in grams consumed during a food intake session and percent of
the averaged weekly baseline RW activity. Planned comparisons were used to compare
each treatment to the VEH group.

Results
Acquisition of Chocolate Binging Behavior
Analysis of the acquisition period of chocolate binge-like eating behavior (Figure
7) using a repeated measures ANOVA found an overall significant effect of binge
session [F(8, 56) = 8.214, p < 0.001)]. A significant linear [F(1, 7) = 16.173, p = 0.005)]
contrast was seen highlighting the increase in chocolate consumption across sessions.

Effect of LDX administration during T-Maze sessions
A repeated measures ANOVA of the LDX test sessions in the maze (Figures 8
and 9) revealed a significant overall effect of LDX treatment on percent baseline
chocolate consumption [F(5, 35) = 7.879, p < 0.001)], but no significant effect on
percent baseline RW activity [F(5, 35) = 1.254, p > 0.3]. Planned comparisons revealed
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that LDX significantly reduced chocolate consumption at all but the lowest dose of LDX
(p < 0.05) when compared to the VEH treatment.

Discussion
The overall purpose of these studies was to characterize the effects of the damphetamine pro-drug LDX on intake of chocolate and lab chow, as well as two
different effort-based choice tasks, one entirely based upon food reinforcement and the
other comparing two different options (i.e. T-maze choice of RW vs. chocolate intake).
These studies were done in female rats that were previously exposed to different types
of food (e.g. chocolate or chow) under conditions that mimic previously used binge-like
eating models (Vickers et al. 2015). Clinical research shows the prevalence of BED is
greater in the female population (Dingemans et. al 2002, Kessler et. al 2013, Hutson et.
al 2018) with twelve-month and life time prevalence rates being 0.8% and 2% in males
and 1.6% and 3.5% in females respectively (Hudson et al. 2007). Therefore, it was
deemed important to conduct this research in female rats in order to better mimic what
is seen in the human population.
Our results for chocolate binge consumption and body weights from experiment
one are consistent with what was reported in the literature in studies employing a similar
rat model (Corwin and Wojnicki 2006, Vickers et al. 2015). Random, intermittent, short
periods of access of chocolate led to a robust and significant increase in chocolate
intake over the repeated sessions (Fig. 1). This was attenuated slightly when chow was
added to the binge sessions and with the removal of food restriction (appendix Fig. 1).
This attenuation of chow intake was also seen in the LChE group upon the removal of
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food restriction but in a much larger degree than that in the CE group (appendix Fig. 2).
The significant increase in body weights for both CE and control animals over the
course of the study illustrates the natural growth of the rats over time, but there was no
significant difference in body weights between the CE and control rats, and no
significant group x week interaction (Figure 2), which is consistent with much of the
literature on binge-like eating models in rodents (Hagan et al. 2002; Corwin et al. 2011,
2016; Vickers et al. 2015; Smail-Crevier et al. 2018). In this regard, it is worth
emphasizing that although BED is more commonly diagnosed in obese individuals, it
also is seen in individuals within the normal BMI range (Bruce and Wilfley 1996; Hudson
et al. 2007).
The d-amphetamine pro-drug LDX became an approved treatment for BED in
2015. In the case of LDX, d-amphetamine (the active moiety) is covalently bound to the
amino-acid L-lysine (inactive) via an amide linking group, and the d-amphetamine only
becomes active once it is metabolized (Heal et. al 2013). This leads to a slow release of
d-amphetamine and longer lasting effects when compared to d-amphetamine on its
own. In the clinical setting, LDX has been shown to significantly reduce the number of
binge eating days/week (McElroy et al. 2016). The results of the present food intake
studies showed that LDX produced a robust suppression of both chocolate and chow
intake in the CE group (Fig. 3). There was a trend towards a reduction in lab chow
intake during the binge sessions in the LChE group (Figure 4), but due to a small
sample size (n=7) this effect did not reach statistical significance. Nevertheless, it can
also be seen in Table 1 that the effect size for the action of LDX in the LChE group was
quite large, and roughly comparable to that seen in the CE group.
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In terms of results from the operant experiment, there was an overall significant
reduction of lever pressing induced by LDX that was seen across both groups. There
was an overall significant effect of LDX on chow intake, however, there also was a
significant group x drug treatment interaction. It appears that a major source of the
interaction was due to the high consumption of chow in the CE group compared to the
control group after VEH treatment. This difference allowed for a significant reduction in
lab chow consumption in the CE group, but there may not have been a significant
reduction in the control group due to a floor effect. Given this pattern of results, it is
reasonable to suggest that with the induction of the binging behavior in the CE group,
these animals also consumed more chow during the operant sessions compared to the
control group, and that this led them to be more sensitive to the effects of LDX in that
setting.
It is important to point out that these drug studies were performed under
conditions in which the animals were not food restricted. Food restriction is generally
useful in order to have rats emit large numbers of responses for food reinforcement.
Thus, food restriction was used during the initial portion of the operant training.
However, it was decided to remove the rats from food restriction after initial acquisition
in order to better mimic what is seen clinically in people with BED, as well as in other rat
models of binging behavior. Once food restriction was removed, we observed lower
levels of both lever pressing and food intake in the rats (appendix Figs. 3 & 4). It is
possible that more robust results in the operant study would have been seen if the rats
had continued on food restriction.
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The induction of the binge-like consumption of chocolate in the T-maze study
varied slightly from what was seen in the operant task. This was due to the fact that
once the T-Maze task was underway, rats only received chocolate in the maze. The rats
completing the RW task were also not food restricted at any point of the study. Even
with these variations from the protocol in experiment one, a robust increase in chocolate
intake was seen (Fig. 7) with the use of random, intermittent, short periods of access to
chocolate. This finding adds to the already established literature that food restriction is
not an important factor in the development of binging behavior in animal models (Avena
et al. 2006; Corwin & Wojnicki 2006), and also what is seen in the BED human
population, with whom hunger is not always a driving factor of binging episodes
(Brownley, Berkman, Sedway, Lohr, & Bulik, 2007; Davis et al., 2007).
The purpose of developing a novel task that pits two reinforcing behaviors
against one another was intended to clarify some of the factors mediating the actions of
LDX. Due to the appetite suppressant effects previously mentioned, it becomes difficult
to say the results we observed in the operant task, which is an entirely food motivated
task, are not simply due to the fact the rat is no longer hungry. The results from the RW
task showed a similar pattern of chocolate intake seen in both the strict binge
consumption and operant tasks of experiment one, with a significant reduction of intake
in a dose dependent manner (Fig. 8). Percent of baseline analyses were used due to
the fact that the rats varied greatly from one another in their intakes. It was not
surprising that there was a reduction in intake of chocolate given the results of
experiment one and the previously mentioned literature on LDX’s ability to attenuate
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binging behaviors in both rat models and human participants (Hagan et al. 2002; Corwin
et al. 2011, 2016; Vickers et al. 2015; Smail-Crevier et al. 2018; McElroy et al. 2016).
Amphetamine exposure induces differential alterations across multiple activities
based on the baseline level of behavior and the dose given. Rate-dependency is a druginduced change in operant behavior in which schedules of reinforcement with high rates
of responding will yield decreases in responding with the administration of a stimulant,
while those with low baseline rates tend to increase (Dews 1958). RW activity was high
in this group of rats, with an average of 252+ 6.33 rotations of the RW in 30 minutes.
Lyon and Robbins (1978) highlighted the fact that different doses of psychomotor
stimulants elicit different behavior with low doses producing an increase switching from
one thing to another with high doses resulting in perseveration and stereotypy. LDX
administration had no significant effect on RW activity but there was a trend towards a
reduction of activity as doses of LDX increased (Fig. 9). Due to the high activity prior to
drug exposure, it appears this task may be subject to rate-dependent effects, and it is
also possible that, with the increasing doses of LDX, rats began engaging in other
behaviors (i.e. increased exploration of maze, rearing, etc.) that lead to a decrease in
the amount of RW activity. Serwatkiewicz at al. (2000) found a similar phenomenon with
rats exposed to d-amphetamine. They found a significant decrease in RW activity at the
highest doses of d-amphetamine administered, and concluded that this was due to an
increase of stereotypic behavior. It is likely that with a higher N, the reduction in RW
activity would have been found to be significant.
Overall, it is clear that LDX reduces intake of the highly palatable chocolate.
However, it also seems evident that the effect of LDX is not limited to chocolate

18

consumption. Thus, a part of the effect of LDX appears to be a general suppression of
food intake, as indicated by the reductions in chow intake that also were seen in
experiment one. Moreover, LDX suppressed food-reinforced PROG responding across
both the chocolate exposure and control groups. Comparing this with the results seen in
the T-Maze task, this reduction in lever pressing could also be attributed to an increase
in alternative activities, similar to the decrease in RW activity seen in experiment two.
Previous studies have shown that LDX suppresses chow intake in rats in the context of
studies using binge-like eating procedures (Vickers et al., 2015), although this point was
not highly emphasized in that paper. The active moiety in LDX, d-amphetamine, has
been shown to induce appetite suppressant effects, thus leading to its use as a weight
loss drug for several decades (Coleman 2005). This is consistent with the fact that a
general suppression of appetite has been reported as a side effect of using LDX to treat
BED in humans (Citrome 2015, McElroy et al. 2016; Ward and Citrome 2018).

Figures

Chocolate Exposure (CE) Group:
Acquisition of Binge Behavior
14
12

19

Chocolate
Chow

Fig. 1. Chocolate and Chow intakes for CE group over the course of acquisition of binge
eating behavior (Mean + SEM intake in grams). Coinciding with introduction to lab chow
during operant task, chow was introduced during 6th binge session. An increase in
chocolate intake was seen before the addition of chow at which put intake was slightly
reduced.
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Fig. 2. Weights of CE and control animals (Mean + SEM body weight in grams) during a
24-week period. Both groups showed steady increases in weight with a significant
overall effect due to week but no significant weight difference between groups, or group
x week interaction.
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Fig. 3. The effects of LDX on chocolate and chow consumption in the CE group during
the 120-minute binge session. Rats (n = 15) received IP injections of vehicle (VEH),
0.1875, 0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+ SEM) chocolate or chow
consumption (in grams) during 120-minute binge session shown. LDX dose significantly
different from VEH for chow, *p < 0.05; LDX dose significantly different from VEH for
chocolate, # p < 0.05.

22

Lab Chow Exposure
(LChE) Group
8
Chow-Chow
Chow
Exposure Group

6

4

Chow Intake (g)

Chow Intake (g)

8

6

+ +

4

2

2
0
VEH

0.1875

0.3750

0.7500

1.5000

Dose LDX (mg/kg)

0
VEH

0.1875

0.3750

0.7500

1.5000

Dose LDX (mg/kg)
Fig. 4. The effects of LDX on chow consumption in the LChE group during the 120minute binge session. Rats (n = 8) received IP injections of vehicle (VEH), 0.1875,
0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+-SEM) chow consumption (in grams)
during 120-minute binge session shown. + LDX dose approached difference from VEH,
0.05 > p < 0.1.
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Chocolate Exposure (CE) Group vs
Control Group Lever Pressing
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Fig. 5. The effects of LDX on lever pressing in the CE and control groups during the 30minute operant session. Rats (n = 30) received IP injections of vehicle (VEH), 0.1875,
0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+ SEM) number of lever presses
during 30-minute operant session (PROG/chow choice) shown. LDX dose significantly
different from VEH, **p < 0.001.
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CE Group vs Control Group
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Fig. 6. The effects of LDX on chow consumption in the CE and control groups during
the 30-minute operant session. Rats (n = 30) received IP injections of vehicle (VEH),
0.1875, 0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean (+ SEM) consumption of chow
during 30-minute operant session (PROG/chow choice) shown. LDX dose significantly
different from VEH, *p < 0.05, **p < 0.001. Significant dose by group interaction # p <
0.05. Difference between groups +0.05 < p < 0.1.
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T-Maze Group:
Acquisition of Binge Behavior
9

Chocolate Intake (g)

8
7
6
5
4
3
2
1
0

2

4

6

8

10

Binge Session
Fig. 7. Chocolate intake for T-Maze group over the course of acquisition of binge eating
behavior (Mean + SEM intake in grams). An increase in chocolate intake was seen over
the course of exposure.
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Fig. 8. The effects of LDX on the percentage of averaged 3 day baseline of chocolate
consumption. Rats (n = 8) received IP injections of vehicle (VEH), 0.09375, 0.1875,
0.375, 0.75, and 1.5 mg/kg doses of LDX. Mean of percent baseline (+ SEM)
consumption of chocolate during 30-minute T-Maze session shown. LDX dose
significantly different from VEH, *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 9. The effects of LDX on the percentage of averaged 3 day baseline of RW activity.
Rats (n = 8) received IP injections of vehicle (VEH), 0.09375, 0.1875, 0.375, 0.75, and
1.5 mg/kg doses of LDX. Mean of percent baseline (+ SEM) RW activity determined
through RW rotations during 30-minute T-Maze session shown. There was a trend
towards a decrease in RW activity by LDX in a dose dependent manner.
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Appendix Fig 1. Chocolate and Chow intakes for CE group over the course of 26 binge
sessions. Coinciding with introduction to lab chow during operant task, chow was
introduced during 6th binge session. An intake of both foods was reduced once non-food
restriction began.
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Appendix Fig 2. Chow intake reduced after non-food restriction for both CE and LChE
groups during binge eating sessions.
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Appendix Fig 3. Weekly average lever pressing for both CE and control groups during
30 minute PROG ratio/feeding task throughout a 20-week period. Groups were food
restricted during Weeks 1-6 and non-food restricted Weeks 7-20. Concurrently available
lab chow was introduced at the start of Week 2. Reward was plain high carbohydrate
pellets weeks 1-11 and chocolate flavored weeks 12-20.
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Appendix Fig 4. Chow intake during operant session for both CE and control groups
during 30 minute PROG ratio/feeding task throughout a 20-week period. Groups were
food restricted during Weeks 1-6 and non-food restricted Weeks 7-20. Shifting from
food restriction to non-food restriction decreased chow intake in both groups.
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